Bronchial Artery and Non-bronchial Systemic Artery Embolization for the Treatment in Patients with Hemoptysis: Analysis of Efficacy of Gelfoam Single Use

Chung, Seok Kyun; Kim, Jae Kyu; Yoon, Woong; Kim, Yun‐Hyeon; Park, Jin Gyoon; Kang, Heoung Keun

doi:10.3348/jkrs.2003.49.1.15

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they presented a controversy about which of gelfoam or PVA was the more effective embolic agent ( 15 , 16 ). According to the report by Chung et al ( 17 ), if an initially successful embolization was performed, the recurrence risk by gelfoam itself in previously embolized vessels was low, and hence there was no definite difference with other results, despite gelfoam being more absorbable in theory. Some authors also reported that there was no difference in the success rates among the various embolic agents ( 14 , 18 ), and no difference in the results was noted among gelfoam and other non-absorbable agents ( 18 ).…”

Section: Discussionmentioning

confidence: 98%

“…According to the report by Tanaka et al ( 13 ), causes of recurrent hemoptysis include recanalization and reperfusion. Reperfusion is achieved by newly developed collateral vessels as underlying diseases progress with time ( 17 ). Thus, in our study, we set a follow-up period of 12 months to have a minimal impact on the recurrence risk from collateral vessels due to underlying diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Effectiveness of Embolic Agents for Bronchial Artery Embolization: Gelfoam versus Polyvinyl Alcohol

et al. 2010

View full text Add to dashboard Cite

ObjectiveThe purpose of this study was to compare the results of different agents for bronchial artery embolization of hemoptysis.Materials and MethodsFrom March 1992 to December 2006, a bronchial artery embolization was performed on 430 patients with hemoptysis. The patients were divided into three groups. Group 1 included 74 patients treated with a gelfoam particle (1×1×1 mm), while group 2 comprised of 205 patients treated with polyvinyl alcohol (PVA) at 355-500 µm, and group 3 included 151 patients treated with PVA at 500-710 µm. We categorized the results as technical and clinical successes, and also included the mid-term results. Retrospectively, the technical success was compared immediately after the procedure. The clinical success and mid-term results (percentage of patients who were free of hemoptysis) were compared at 1 and 12 months after the procedure, respectively.ResultsNeither the technical successes (group 1; 85%, 2; 85%, 3; 90%) nor the clinical successes (group 1; 72%, 2; 74%, 3; 71%) showed a significant difference among the 3 groups (p > 0.05). However, the mid-term results (group 1; 45%, 2; 63%, 3; 62%) and mid-term results excluding the recurrence from collateral vessels in each of the groups (group 1; 1 patient, 2; 4 patients, 3; 2 patients) showed that group 1 was lower than the other two groups (p < 0.05). No significant difference was discovered for the mid-term results between groups 2 and 3. Moreover, the same results not including incidences of recurrence from collateral vessels also showed no statistical significance between the two groups (p > 0.05).ConclusionPolyvinyl alcohol appears to be the more optimal modality compared to gelfoam particle for bronchial artery embolization in order to improve the mid-term results. The material size of PVA needs to be selected to match with the vascular diameter.

show abstract